

Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience

Lorenzo Cani,^{1,2} Sara A. Scott,³ Danielle Roberts,² Nisha S. Joseph,² Craig C. Hofmeister,² Vikas A. Gupta,² Madhav V. Dhodapkar,² Sagar Lonial,² Ajay K. Nooka² and Jonathan L. Kaufman²

¹Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, Torino, Italy; ²Winship Cancer Institute of Emory University, Atlanta, GA, USA and ³Emory Healthcare, Atlanta, GA, USA

Correspondence: L. Cani
lorenzocani1@outlook.it


Received: May 21, 2025.
Accepted: August 20, 2025.
Early view: September 4, 2025.

<https://doi.org/10.3324/haematol.2025.288187>

©2026 Ferrata Storti Foundation
Published under a CC BY-NC license 

SUPPLEMENTAL

Figure S1. Cumulative incidence of first grade ≥ 3 infection in patients treated with BCMA and GPRC5D-directed agents.



Abbreviations. BCMA, B-cell maturation antigen; GPRC5D, G-protein-coupled receptor family C group 5 member D.